Vollständiger Abstract
Worum geht es in dieser Arbeit?
8004 Background: The role of allogeneic stem cell transplantation (alloSCT) in high-risk aggressive NHL is poorly defined; the role of graft-versus-lymphoma effect is unclear. Reduced intensity conditioning has shown limited efficacy in patients with refractory disease. Methods: Patients with primary refractory disease, early relapse ( grade I correlated with improved PFS (HR 0.45, p=0.0088). Patients with refractory disease or early relapse (n=60) experienced PFS at 3y of 33%. Conclusions: Lymphoma-debulking (high-dose) chemotherapy followed by alloSCT shows excellent results in heavily pretreated patients with early relapse or primary refractory aggressive lymphoma. There was evidence of graft-versus-lymphoma activity in this setting. For patients with a fully matched (10/10) related or unrelated donor the results compare favorably to autoSCT or alloSCT following reduced-intensity conditioning.
Bibliografischer Nachweis
Publikationsdaten
- Autor:innen
- Bertram Glass, Justin Hasenkamp, Gerald Wulf, Peter Dreger, Michael Pfreundschuh, Martin Gramatzki, Gerda Silling, Christian Wilhelm, Matthias Zeis, Sebastian Pfeiffer, Lorenz Trümper, Norbert Schmitz
- Quelle
- Journal of Clinical Oncology
- Publikation
- 2012-01-01
- Band / Ausgabe
- Nicht angegeben
- Seiten
- Nicht angegeben
- ISSN / ISBN
- 0732-183X, 1527-7755
- Zitationen
- 2 laut Crossref
- Referenzen
- 0 hinterlegt
Zitieren
Zitierfähiger Nachweis
Bertram Glass, Justin Hasenkamp, Gerald Wulf, Peter Dreger, Michael Pfreundschuh, Martin Gramatzki, Gerda Silling, Christian Wilhelm, Matthias Zeis, Sebastian Pfeiffer, Lorenz Trümper, Norbert Schmitz (2012). High-dose chemotherapy followed by allogeneic stem cell transplantation in high-risk relapsed and refractory aggressive non-Hodgkin lymphoma: Results of a prospective study of the German high-grade non-Hodgkin lymphoma study group. Journal of Clinical Oncology. https://doi.org/10.37895/2071-8004-2025-29-2-50-57